Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study

AIDS

Volumn 24, Issue 11, 2010, Pages 1697-1707

  Martinez, Esteban ^a   Larrousse, María ^a   Llibre, Josep M ^b   Gutierrez, Felix ^c   Saumoy, Maria ^d   Antela, Antonio ^e   Knobel, Hernando ^f   Murillas, Javier ^g   Berenguer, Juan ^h   Pich, Judit ^a   Pérez, Ignacio ^a   Gatell, José M ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e Hospital de Santiago   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

clinical trial; raltegravir; ritonavir boosted protease inhibitors; simplification

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; CREATININE; DARUNAVIR; FOSAMPRENAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL KIDNEY DISEASE; BACTERIAL MENINGITIS; BACTERIAL PNEUMONIA; BONE DISEASE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COLITIS; COLON TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOENCEPHALOPATHY; LIVER DISEASE; LUNG EDEMA; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE DISEASE; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOSIS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL; UROGENITAL TRACT DISEASE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIPIDS; MALE; MIDDLE AGED; PYRROLIDINONES; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 77954348583     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833a608a     Document Type: Article

References (28)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
2. Panel de expertos de Gesida y Plan Nacional sobre el SIDA. Documento de consenso de Gesida/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infecta-dos por el virus de la inmunodeficiencia humana: actualización enero 2010. http://www.gesida.seimc.org/ pcientifica/fuentes/DcyRc/gesidadcyrc2010-DocconsensoTARGESIDA-PNS-verpc.pdf. [Accessed 19 March 2010]
3. Clumeck N, Dedes N, Pozniak A, and the EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults in Europe. http://www. europeanaidsclinicalsociety.org/guidelinespdf/EACS- EuroGuidelines2009FullVersion.pdf. [Accessed 19 March 2010]
4. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001; 2:105-113.
5. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
6. Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997; 41:898-905.
7. Shafran SD, Mashiter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 2005; 6:421-425.
8. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-näive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009; 52:350-356.
9. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-näive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796-806.
10. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007; 369:1261-1269.
11. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
12. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502.
13. Division of AIDS (DAIDS). Table for Grading the Severity of Adult and Pediatric Adverse Events. Version 1. 0. December 2004 (Clarification dated August 2009). http://rcc.tech-res.com/safetyandpharmacovigilance. [Accessed 19 March 2010]
14. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355-365.
15. - 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1-19.
16. Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, Lazzarin A, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003; 17:1741-1751. (Pubitemid 37000092)
17. Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, et al. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther 2008; 13:927-936.
18. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17:873-890.
19. Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. Boca Raton: Chapman &Hall/CRC; 1999.
20. Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375:396-407.
21. Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349:1036-1046.
22. Marcelin AG, Ceccherini-Silberstein F, Perno CF, Calvez V. Resistance to novel drug classes. Curr Opin HIV AIDS 2009; 4:531-537.
23. Rosenblum M, Deeks SG, van der Laan M, Bangsberg DR. The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PloS ONE 2009; 4:e7196.
24. Reekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, van Lunzen J, et al. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after treatment change. HIV Med 2010. [Epub ahead of print]
25. Martinez E, Leyes P, Ros E. Effectiveness of lipid-lowering therapy in HIV patients. Curr Opin HIV AIDS 2008; 3:240-246.
26. National Cholesterol Education Program: third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Risk assessment tool for estimating 10-year risk of developing hard CHD (myocardial infarction and coronary death). http://hp2010.nhlbihin.net/atpIII/calculator.asp?usertype=prof. [Accessed 19 March 2010]
27. Martinez E, Arribas J, Lopez-Aldeguer J, Gutierrez F, Miralles C, Lozano F, et al. Factors associated with a high cardiovascular risk in HIV-infected patients in Spain: a multicenter, nationwide, cross-sectional study. In: Program and Abstracts of the Conference of Retrovirus and Opportunistic Infections. Boston, Massachusetts; 22-25 February 2005; abstract 870.
28. Worm S, Kamara A, El-Sadr W, Kirk O, Fontas E, Reiss P, et al. Triglycerides and the risk of myocardial infarction in the D:A:D study. In: Program and Abstracts of the Conference of Retrovirus and Opportunistic Infections. San Francisco, California; 16-19 February 2010; abstract 127.